Suprefact Depot: Advanced Drug Delivery with Nomisma’s PLGA

Suprefact Depot, a sustained-release formulation containing Buserelin Acetate, has emerged as a breakthrough in the treatment of hormone-dependent conditions. As a luteinizing hormone-releasing hormone (LHRH) agonist, it is widely used to manage advanced prostate cancer and endometriosis. With convenient dosage options of 6.3 mg (every 2 months) and 9.45 mg (every 3 months), it ensures patient compliance and effective therapy.

PLGA 75:25: The Backbone of Controlled Release

The formulation of Suprefact Depot leverages PLGA 75:25, a biodegradable polymer composed of:

  • Composition: 75% lactic acid and 25% glycolic acid.
  • Molecular Weight: 20,000 – 50,000 g/mol.
  • Inherent Viscosity (IV): 0.4 – 0.6 dL/g.

These properties allow precise control over the degradation rate and drug release profiles, making it ideal for sustained-release applications.

Applications of Suprefact Depot

Suprefact Depot’s unique formulation finds its primary applications in:

  1. Prostate Cancer Therapy:
    • Suppresses testosterone levels to slow disease progression.
  2. Endometriosis Management:
    • Reduces estrogen production, alleviating symptoms such as pain and inflammation.
  3. Fertility Treatments:
    • Occasionally utilized in controlled ovarian stimulation protocols.

Why Choose Nomisma’s PLGA?

Nomisma Healthcare specializes in manufacturing high-quality PLGA tailored for pharmaceutical applications. The following features set Nomisma’s PLGA apart:

  • High Purity & Biocompatibility: Ensures safety and efficacy in drug formulations.
  • Customizable Properties: Offers tailored molecular weight and IV ranges to suit specific needs.
  • Regulatory Compliance: Nomisma’s PLGA meets stringent standards for FDA-approved formulations.

Driving Innovation in Drug Delivery

Suprefact Depot exemplifies the transformative potential of Nomisma’s PLGA in advanced drug delivery systems. By ensuring controlled drug release and patient adherence, it highlights how innovative polymer technologies can redefine therapeutic outcomes.

References

  1. Klingmüller, D., & Schweikert, H. U. (1986). Buserelin acetate in the treatment of advanced prostate cancer. Cancer Treatment Reviews, 13(Suppl C), 47–52. DOI:10.1016/0305-7372(86)90008-7
  2. Jain, R. A. (2000). The manufacturing techniques of various drug-loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices. Biomaterials, 21(23), 2475–90. DOI:10.1016/S0142-9612(00)00115-0
  3. Nomisma Healthcare. (2024). High-purity PLGA for advanced pharmaceutical applications.